297 related articles for article (PubMed ID: 9806184)
1. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
Linet OI; Ogrinc FG
N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
[TBL] [Abstract][Full Text] [Related]
3. [Prostaglandin E1 (PGE1) in diagnosis and long-term therapy of erectile dysfunction].
Derouet H; Weirauch A; Bewermeier H
Urologe A; 1996 Jan; 35(1):62-7. PubMed ID: 8851852
[TBL] [Abstract][Full Text] [Related]
4. [Prostaglandin E1 in the diagnosis and therapy of erectile disorders].
Loran OB; Segal AS; Shcheplev PA
Urol Nefrol (Mosk); 1995; (4):35-8. PubMed ID: 7571200
[TBL] [Abstract][Full Text] [Related]
5. The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction.
Vick RN; Benevides M; Patel M; Parivar K; Linnet O; Carson CC
J Urol; 2002 Jun; 167(6):2618-23. PubMed ID: 11992097
[TBL] [Abstract][Full Text] [Related]
6. Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.
Chen RN; Lakin MM; Montague DK; Ausmundson S
J Urol; 1996 Jan; 155(1):138-40. PubMed ID: 7490812
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction.
Tsai YS; Lin JS; Lin YM
Eur Urol; 2000 Aug; 38(2):177-83. PubMed ID: 10895010
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China.
He L; Wen J; Jiang X; Chen H; Tang Y
Andrologia; 2011 Jun; 43(3):208-12. PubMed ID: 21486416
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians.
Pangkahila WI
Asian J Androl; 2000 Sep; 2(3):233-6. PubMed ID: 11225984
[TBL] [Abstract][Full Text] [Related]
10. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
[TBL] [Abstract][Full Text] [Related]
13. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.
Bratus D; Hlebic G; Hajdinjak T
Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic.
Armstrong DK; Convery A; Dinsmore WW
Ulster Med J; 1994 Apr; 63(1):18-22. PubMed ID: 8658990
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in patients using self-administered intracavernous injections of prostaglandin E1 for erectile dysfunction.
Gheorghiu S; Godschalk M; Gentili A; Mulligan T
J Urol; 1996 Jul; 156(1):80-1. PubMed ID: 8648844
[TBL] [Abstract][Full Text] [Related]
16. Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction.
Porst H; van Ahlen H; Block T; Halbig W; Hautmann R; Löchner-Ernst D; Rudnick J; Staehler G; Weber HM; Weidner W
Vasa Suppl; 1989; 28():50-6. PubMed ID: 2609244
[TBL] [Abstract][Full Text] [Related]
17. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
Potempal AJ; Potempa DM; Görlich HD; Stolpmann RM
Arzneimittelforschung; 2007; 57(6):299-308. PubMed ID: 17688074
[TBL] [Abstract][Full Text] [Related]
18. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity.
Raina R; Pahlajani G; Agarwal A; Zippe CD
BJU Int; 2007 Dec; 100(6):1317-21. PubMed ID: 17850385
[TBL] [Abstract][Full Text] [Related]
19. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.
Padma-Nathan H; Hellstrom WJ; Kaiser FE; Labasky RF; Lue TF; Nolten WE; Norwood PC; Peterson CA; Shabsigh R; Tam PY; Place VA; Gesundheit N
N Engl J Med; 1997 Jan; 336(1):1-7. PubMed ID: 8970933
[TBL] [Abstract][Full Text] [Related]
20. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates.
Polito M; d'Anzeo G; Conti A; Muzzonigro G
BJU Int; 2012 Dec; 110(11 Pt C):E954-7. PubMed ID: 23078100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
